Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers

Area of Science:

• Immunology and Oncology
• Cancer Immunotherapy

Background:

• The PD-1/PD-L1 axis is a critical immunosuppressive pathway in T-cell responses, vital for immune homeostasis.
• The tumor microenvironment's complexity significantly influences the success of cancer immunotherapy strategies.

Purpose of the Study:

• To review the function of the PD-1/PD-L1 signaling pathway in cancer.
• To discuss the immunological, genomic, epigenetic, and transcriptomic landscape of patients undergoing anti-PD-1/PD-L1 therapy.
• To provide an overview of ongoing clinical trials for PD-1/PD-L1 antibodies.

Main Methods:

• Literature review focusing on the PD-1/PD-L1 pathway.
• Analysis of immunological, genomic, and transcriptomic data in cancer patients.
• Summary of clinical trial data for anti-PD-1/PD-L1 therapies.

Main Results:

• Immune checkpoint inhibitor (ICI) therapy, including anti-PD-1/PD-L1, has transformed cancer treatment across various malignancies.
• Characterizing the tumor microenvironment aids in distinguishing responders from non-responders to ICI therapy.
• Ongoing research aims to improve patient selection, understand resistance mechanisms, and discover novel biomarkers.

Conclusions:

• Understanding the PD-1/PD-L1 pathway and associated tumor landscapes is crucial for optimizing immunotherapy.
• Further research into biomarkers and clinical trials is essential to maximize the efficacy of anti-PD-1/PD-L1 therapies.